Invaryant and CardieX partner to expand RPM during clinical trials

ASX-listed health tech firm CardieX announced its subsidiary, medical technology company ATCOR, will partner with AI-enabled health tech company Invaryant to conduct joint clinical research on maternal health and cardiovascular disease.  

Invaryant’s health platform will integrate digital vascular biomarkers gathered from ATCOR’s SphygmoCor arterial technology, which measures the central aortic pressure waveform, to allow for closer patient monitoring of risk factors associated with hypertensive disorders. 

Georgia-based Invaryant will also utilize the CONNEQT Pulse, which measures central blood pressure, to obtain multiple arterial health indicators. Health analytics platform CONNEQT is another subsidiary of CardieX. 

“It’s exciting to see patient-driven technologies expand and enhance decentralized clinical trial outcomes. The ATCOR and Invaryant partnership will integrate the best in personalized vascular biometric monitoring with Inara’s advanced AI and machine learning [Invaryant’s AI bot platform] to help educate patients about their vascular health and improve patient-reported outcomes. I’m excited to leverage our combined technologies for the best patient experience and access to the most meaningful data,” Craig Cooper, group CEO of the CardieX companies, said in a statement. 


In November, the Australian company announced it acquired Silicon Valley-based cardiovascular sensor company Blumio, which develops cardiovascular sensor algorithms and data analytics tools. 

Earlier this year, CardieX and Mobvoi, an AI-enabled wearable company, launched TicWatch GTH Pro, a consumer smartwatch that utilizes ATCOR’s SphygmoCor technology to monitor heart health.

Related Posts